Noom vs Hims: GLP-1 Programs & Personalization

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Noom and Hims represent two contrasting approaches to telehealth-delivered GLP-1 programs. Noom operates primarily as a behavioral-change platform that integrates medication options, while Hims functions as a direct-to-consumer telehealth provider offering multiple GLP-1 medications alongside consultations. Both attract patients seeking convenient access to GLP-1 treatment, yet their clinical models, personalization strategies, and provider involvement differ substantially.

If you're evaluating these platforms or considering GLP-1 therapy generally, understanding their operational differences matters. PlexusDx takes a precision-wellness approach by combining licensed compounding pharmacy services with genetic insights into peptide metabolism—tools that can complement your conversation with any qualified provider, whether through Noom, Hims, or your primary care physician.

Noom's Behavioral Integration Model

Noom was founded as a behavior-change application focused on habit formation and psychological eating patterns. The platform later added GLP-1 medication access, positioning it as an adjunct to its core behavioral curriculum. Noom's clinical model emphasizes habit coaching, food logging, and group support alongside medication prescription through licensed physicians.

Noom's GLP-1 program integrates behavioral tracking with medication management. Users access the app's behavioral coaching tools and can receive prescriptions for semaglutide or tirzepatide following telehealth consultations. The platform's differentiation relies on combining medication with structured behavioral intervention rather than on medication selection alone.

Hims' Direct-to-Consumer Telehealth Framework

Hims operates as a comprehensive telehealth platform offering GLP-1 medications alongside treatments for erectile dysfunction, hair loss, and other conditions. The model prioritizes rapid physician consultation, medication delivery, and ongoing clinical monitoring. Hims provides access to branded GLP-1 options (such as semaglutide for weight loss) and compounded formulations, depending on availability and prescriber judgment.

Hims' clinical structure relies on licensed physicians reviewing patient health history and determining medication eligibility. The platform emphasizes convenience and speed of access; patients complete an online assessment, connect with a provider, and receive prescriptions shipped directly. Ongoing care includes periodic check-ins with clinicians to monitor response and adjust dosing.

Clinical Support Model Comparison

Both platforms employ licensed physicians to review medical history and authorize prescriptions. However, their clinical supervision architecture differs. Noom's physicians operate within a behavior-change framework and rely on the platform's coaching team for ongoing engagement. Hims' physicians manage patients more independently, with clinical oversight focused on medication tolerability and weight-loss progress.

Dimension	Noom	Hims	What It Means
Primary Model	Behavioral platform with medication add-on	Telehealth pharmacy-first service	Noom emphasizes habit change; Hims emphasizes medication access
Physician Role	Prescription review within behavioral context	Independent medication management	Noom integrates med decisions with coaching; Hims treats meds as primary intervention
Personalization Approach	Behavior tracking, food logging, habit patterns	Medical history, comorbidities, prior medication trials	Noom uses behavioral data; Hims uses clinical data for selection
Ongoing Monitoring	App-based coaching plus periodic clinical check-in	Scheduled telehealth follow-ups with clinician	Noom offers continuous app engagement; Hims relies on scheduled visits
Medication Options	Typically semaglutide or tirzepatide (brand/compounded varies)	Branded and compounded semaglutide and tirzepatide options	Both offer multiple medications; availability may differ by location
Cost Model	Subscription (app + medication bundled or separate)	Pay-per-visit or monthly subscription plus medication costs	Noom emphasizes bundling; Hims itemizes consultation and medication separately

Medication Selection and Personalization Factors

Both Noom and Hims rely on standard clinical criteria—BMI, medical history, medication interactions, and prior GLP-1 experience—when determining which medication to prescribe. Neither platform currently incorporates genetic testing into their standard personalization workflow, though both assess individual response through ongoing monitoring.

Genetic variation in GLP-1 receptor pathways, FTO signaling, and GIPR expression can influence how individuals respond to semaglutide or tirzepatide, though individual response remains multifactorial. A qualified provider at either platform can discuss how your medical history informs medication choice. Genetic testing, if pursued separately, can provide additional context about your peptide metabolism predispositions to support that conversation.

Safety, Monitoring, and Medical Eligibility

Both platforms require medical evaluation before prescribing GLP-1 medications. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, uncontrolled hypertension, and certain kidney conditions. Noom and Hims physicians screen for these during their consultation process.

Ongoing safety depends on regular clinical contact. Noom's model integrates app-based symptom tracking with periodic provider check-ins; Hims requires scheduled follow-up visits to assess tolerance and efficacy. Both should monitor for gastrointestinal side effects, injection-site reactions, pancreatitis warning signs, and blood-sugar changes in diabetic patients. If you experience severe nausea, signs of pancreatitis, or allergic reactions, immediate medical attention is necessary regardless of platform.

How PlexusDx Supports a More Personalized Approach

Genetic predispositions in peptide signaling—such as variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)—may influence how your metabolic pathways respond to GLP-1 agonists. These genetic factors do not determine medication response alone, but they can provide context for understanding individual variability in efficacy and side-effect patterns.

PlexusDx offers the Precision Peptide Genetic Test ($99 as an add-on or $298 standalone) to assess your genetic predispositions in these peptide pathways. The test does not predict which medication will work or guarantee outcomes; rather, it may help provide context for a more informed conversation with your healthcare provider about whether GLP-1 therapy aligns with your metabolic profile and which formulation might warrant discussion.

Whether you're considering Noom, Hims, or another provider, genetic insight can complement clinical evaluation. PlexusDx works alongside qualified physicians—it does not replace medical judgment. A licensed provider can interpret your genetic report, discuss how it might relate to your clinical history, and help guide medication selection or adjustment based on both genetic and phenotypic factors.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Noom and Hims GLP-1 programs?

Noom operates as a behavior-change app that added medication; Hims is a telehealth pharmacy platform. Noom emphasizes habit coaching alongside GLP-1 therapy; Hims prioritizes direct medication access and clinical oversight. Both employ physicians, but Noom integrates meds into behavioral coaching, while Hims treats GLP-1 as a primary intervention.

Which platform is better for personalization?

Personalization differs by type. Noom uses behavioral and food-logging data alongside medical history; Hims uses clinical data and prior medication experience. Neither incorporates genetic testing routinely. Your choice depends on whether you prefer behavior-integrated coaching (Noom) or streamlined medication management (Hims).

Do Noom or Hims use genetic testing for GLP-1 selection?

Neither platform includes genetic testing in standard workflows. Both rely on medical history and clinical response. Genetic testing for peptide pathways is available separately through providers like PlexusDx to help contextualize individual variability, though it should inform—not replace—clinical evaluation.

How does PlexusDx compare to Noom or Hims?

PlexusDx provides compounded GLP-1 medications through licensed 503A pharmacies and offers genetic testing for peptide pathway predispositions. PlexusDx is not a telehealth platform like Noom or Hims; it complements them by offering precision-guided medication access and genetic insights to support provider conversations.

Can I use genetic testing if I choose Noom or Hims?

Yes. Genetic testing is independent of your platform choice. PlexusDx Precision Peptide Genetic Test can provide context about your peptide metabolism predispositions, which you can discuss with your Noom or Hims provider to inform medication decisions or adjustments.

What are the safety considerations for both platforms?

Both Noom and Hims screen for contraindications (thyroid cancer history, severe kidney disease, uncontrolled hypertension) and monitor for side effects. Regular clinical contact is essential. Severe nausea, pancreatitis signs, or allergic reactions require immediate medical attention regardless of platform.

Noom vs Hims: Platform Design, Clinical Support, and Personalized GLP-1 Selection

Noom and Hims are two distinct telehealth platforms offering GLP-1 medication programs, each with different business models, clinical oversight structures, and personalization strategies.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →